Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$0.94
-0.5%
$0.94
$0.03
$1.03
$5.59M0.542,709 shs2,402 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$1.27
-0.8%
$1.24
$1.01
$65.00
$5.56M2.24327,134 shs44,411 shs
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
$0.38
$0.38
$0.36
$4.80
$1.43MN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.16
-4.2%
$3.08
$1.75
$9.37
$5.11M1.38828,254 shs62,112 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00%0.00%0.00%0.00%-4.98%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
+0.79%-0.78%+13.27%-8.57%-82.80%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00%0.00%0.00%0.00%0.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.30%-2.94%+4.10%+7.14%+1,525.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.3916 of 5 stars
0.03.00.00.01.90.00.6
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.2445 of 5 stars
0.03.00.00.02.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00
N/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$10.06M0.56N/AN/A$1.66 per share0.56
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A$0.67 per shareN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.37N/AN/A$3.01 per share1.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
-$5.69M-$1.41N/AN/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$51.60M-$78.00N/AN/AN/AN/AN/A-172.89%8/12/2025 (Estimated)
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
-$4.37MN/A0.00N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)

Latest NBSE, FRTX, MBIO, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.05N/A-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
0.40
0.40
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49

Institutional Ownership

CompanyInstitutional Ownership
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
25.04%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
12.37%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
205.97 million5.96 millionNot Optionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1004.38 million952,000Not Optionable
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
403.75 million3.46 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fresh Tracks Therapeutics stock logo

Fresh Tracks Therapeutics NASDAQ:FRTX

$0.94 -0.01 (-0.53%)
As of 02/28/2025

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$1.27 -0.01 (-0.78%)
As of 04:00 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

NeuBase Therapeutics stock logo

NeuBase Therapeutics NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.16 -0.14 (-4.24%)
As of 03:59 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.